

<SEC-DOCUMENT>0001144204-19-027608.txt : 20190522
 <SEC-HEADER>0001144204-19-027608.hdr.sgml : 20190522
 <ACCEPTANCE-DATETIME>20190522090013
 ACCESSION NUMBER: 0001144204-19-027608
 CONFORMED SUBMISSION TYPE: 6-K
 PUBLIC DOCUMENT COUNT: 3
 CONFORMED PERIOD OF REPORT: 20190522
 FILED AS OF DATE: 20190522
 DATE AS OF CHANGE: 20190522

FILER:

COMPANY DATA:

COMPANY CONFORMED NAME: Anchiano Therapeutics Ltd.
 CENTRAL INDEX KEY: 0001534248
 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
 IRS NUMBER: 000000000
 STATE OF INCORPORATION: L3
 FISCAL YEAR END: 1231

FILING VALUES:

FORM TYPE: 6-K
 SEC ACT: 1934 Act
 SEC FILE NUMBER: 001-38807
 FILM NUMBER: 19844334

BUSINESS ADDRESS:

STREET 1: 1/3 HIGH-TECH VILLAGE
 STREET 2: GIVAT RAM, P.O. BOX 39264
 CITY: JERUSALEM
 STATE: L3
 ZIP: 9139102
 BUSINESS PHONE: 972-2-5486555

MAIL ADDRESS:

STREET 1: 1/3 HIGH-TECH VILLAGE
 STREET 2: GIVAT RAM, P.O. BOX 39264
 CITY: JERUSALEM
 STATE: L3
 ZIP: 9139102

FORMER COMPANY:

FORMER CONFORMED NAME: BioCancell Ltd.
 DATE OF NAME CHANGE: 20111104

</SEC-HEADER>

<DOCUMENT>

<TYPE>6-K

<SEQUENCE>1

<FILENAME>tv522194_6k.htm

<DESCRIPTION>FORM 6-K

<TEXT>

<HTML>

<HEAD>

<TITLE></TITLE>

</HEAD>

<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%"> </DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"> </P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">SECURITIES
AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"> </P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">FORM
6-K</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"> </P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> </P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>For
the month of May 2019</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid;
width: 200pt"> </DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT
STYLE="font-size: 14pt; text-transform: uppercase">Anchiano
Therapeutics Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Translation
of registrant's name
into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid;
width: 200pt"> </DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">1/3 High-
Tech Village, Givat Ram, P.O.
Box 39264</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Jerusalem,
9139102 Israel</P>

(Address of
Principal Executive Offices)

Indicate by check
mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F		Form 40-F
-----------	--	-----------

Form 20-F		Form 40-F
-----------	--	-----------

Form 20-F		Form 40-F
-----------	--	-----------

Form 20-F		Form 40-F
-----------	--	-----------

Form 20-F		Form 40-F
-----------	--	-----------

Form 20-F		Form 40-F
-----------	--	-----------

Indicate by
check mark whether the registrant by furnishing
the information contained in this form is also thereby furnishing the information to the Commission
pursuant to Rule 12g3-2(b)
under the Securities Exchange Act of 1934:

Yes		No
-----	--	----

Yes		No
-----	--	----

Yes		No
-----	--	----

Yes		No
-----	--	----

Yes		No
-----	--	----

Yes		No
-----	--	----

On May 22, 2019, Anchiano Therapeutics

Ltd. announced its first quarter 2019 financial results. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">

<TR STYLE="vertical-align: top; background-color: white">

<TD STYLE="width: 0.75in; font-size: 10pt; border-bottom: Black 1pt solid">Exhibit No.</TD>

<TD STYLE="width: 0.1in; padding-bottom: 1pt"> </TD>

<TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">

Description of Exhibit</TD></TR>

<TR STYLE="vertical-align: top; background-color: white">

<TD STYLE="font-size: 10pt; padding-top: 3pt">99.1</TD>

<TD STYLE="padding-top: 3pt"> </TD>

<TD STYLE="font-size: 10pt; padding-top: 3pt">Press Release dated May 22, 2019</TD></TR>

</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->

<DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"> </P></DIV>

<DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"> </P></DIV>

<!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">

<TR STYLE="vertical-align: top; text-align: left">

<TD> </TD>

<TD COLSPAN="2"><P STYLE="margin-top: 0; margin-bottom: 0">Anchiano Therapeutics Ltd.</P>

</TD>

<TD> </TD></TR>

<TR STYLE="vertical-align: top; text-align: left">

<TD STYLE="width: 60%"> </TD>

<TD STYLE="width: 2%"> </TD>

<TD STYLE="width: 28%"> </TD>

<TD STYLE="width: 20%"> </TD></TR>

<TR STYLE="vertical-align: top; text-align: left">

<TD> </TD>

<TD STYLE="white-space: nowrap">By: </TD>

<TD STYLE="border-bottom: Black 1pt solid">/s/ Dr. Frank G. Haluska</TD>

<TD> </TD></TR>

<TR STYLE="vertical-align: top; text-align: left">

<TD> </TD>

<TD> </TD>

<TD COLSPAN="2">Dr. Frank G. Haluska
 Chief Executive Officer</TD></TR>

</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">Dated May 22, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->

<DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"> </P></DIV>

<!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </P>

</BODY>

</HTML>

</TEXT>

</DOCUMENT>

<DOCUMENT>

<TYPE>EX-99.1

<SEQUENCE>2

<FILENAME>tv522194_ex99-1.htm

<DESCRIPTION>EXHIBIT 99.1

<TEXT>

<HTML>

<HEAD>

<TITLE></TITLE>

</HEAD>

<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"> </P>

<P STYLE="margin: 0; text-align: right">Exhibit 99.1</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"> </P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">FOR IMMEDIATE RELEASE </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Anchiano
Therapeutics Reports First Quarter
2019 Financial Results</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT
STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> ‐
<I>Closed \$30.5 million U.S. Initial
Public Offering in February
2019 </I> ‐</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </P>

CAMBRIDGE, Mass., May 22, 2019 - Anchiano Therapeutics Ltd. (Nasdaq and TASE: ANCN) ("Anchiano"), a pivotal-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today reported financial results for its first quarter ended March 31, 2019.

** **

Key Developments and Recent Highlights

** **

	 	 	
Closed an initial public offering ("IPO") of Anchiano's American Depositary Shares ("ADSs") on February 14, 2019, resulting in gross proceeds of \$30.5 million. The ADSs began trading on the Nasdaq Capital Market ("Nasdaq") under the symbol "ANCN."			

** **

	 	 	
Following the IPO, Anchiano's financial resources are expected to meet its needs until the second quarter of 2020.			

** **

	 	 	
Initiated delisting of its ordinary shares from the Tel Aviv Stock Exchange (TASE). The last day the ordinary shares will trade on the TASE is expected to be June 13, 2019, and the ordinary shares are expected to be delisted from the TASE on June 17, 2019.			

** **

"We are pleased with the progress we have made this quarter as a company, with the continued development of inodiftagene, our gene therapy for bladder cancer; our U.S. IPO and Nasdaq listing; and the subsequent steps we have taken to delist from the TASE," stated Frank Haluska, M.D., Ph.D., President and Chief Executive Officer of Anchiano. **"We believe we are now well positioned with a U.S.-based clinical development operation, a strong U.S. shareholder base, a strong balance sheet, and an exciting product candidate in its pivotal phase of development. We look forward to announcing several clinical milestones this**

year as we continue the Codex pivotal clinical trial of inodiftagene for the treatment of early-stage bladder cancer.”</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">First Quarter 2019 Financial Results:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 31, 2019, Anchiano had total cash and cash equivalents of approximately \$32.1 million, compared to approximately \$7.5 million on December 31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses for the first quarter of 2019 were approximately \$4.1 million, compared to approximately \$2.5 million in the first quarter of 2018. The increase was mainly due to an increase in clinical trial expenses, manufacturing expenses and an increase in clinical manpower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses for the first quarter of 2019 were approximately \$1.3 million, compared to approximately \$0.9 million in the first quarter of 2018. The increase was mainly due to an increase in professional and consulting expenses, insurance, rent expenses, and employee options and payroll provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financing expenses, net, in the first quarter of 2019 were approximately \$12.9 million compared to approximately \$0.08 million in the first quarter of 2018. This change was mainly due to changes in the fair value of derivative financial instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 1 -->

<DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"> </P></DIV>

<DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"> </P></DIV>

<!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net loss for the first quarter of 2019 was approximately \$18.4 million, or \$0.70 per share, compared to approximately \$3.5 million, or \$0.37 per share in the first quarter of 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
 </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
About Anchiano</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Anchiano is a pivotal-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, with offices in Cambridge, MA, and Jerusalem, Israel. Anchiano's most advanced product candidate, inodiftagene vixteplasmid, is a gene-therapy product candidate that is in development as a treatment for non-muscle-invasive bladder cancer. For more information on Anchiano, please visit <U>www.anchiano.com.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #263F6A"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Forward-Looking Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">This press release contains “forward-looking statements” that are subject to risks and uncertainties. Words such as “believes,” “intends,” “expects,” “projects,” “anticipates” and “future” or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions, many of which are beyond the control of Anchiano, including, without limitation, the risk factors and other matters set forth in its filings with the Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2018. Anchiano undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Company Contact:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Frank Haluska,
M.D., Ph.D.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">President and
Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><U>info@anchiano.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Investor Contact:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Ashley R. Robinson</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Managing Director</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">LifeSci Advisors, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">617-535-7742</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><U>arr@lifesciadvisors.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </P>

<!-- Field: Page; Sequence: 2 -->

<DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"> </P></DIV>

<DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"> </P></DIV>

<!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">QUARTERLY RESULTS OF OPERATIONS (unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">U.S. dollars in thousands</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">

<TR STYLE="vertical-align: bottom">

<TD STYLE="font-size: 10pt"> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </TD>

<TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Fiscal Quarter Ended March 31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif"> </TD></TR>

<TR STYLE="vertical-align: bottom">

<TD STYLE="font-size: 10pt"> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </TD>

<TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif"> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </TD>

<TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif"> </TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Operating expenses</TD><TD STYLE="font-size: 10pt"> </TD>

<TD STYLE="font-size: 10pt; text-align: left"> </TD><TD STYLE="font-size: 10pt; text-align: right"> </TD><TD STYLE="font-size: 10pt; text-align: left"> </TD><TD STYLE="font-size: 10pt"> </TD>

<TD STYLE="font-size: 10pt; text-align: left"> </TD><TD STYLE="font-size: 10pt; text-align: right"> </TD><TD STYLE="font-size: 10pt; text-align: left"> </TD></TR>

Research and development expenses	
	4,141
General and administrative expenses	
	2,475
Operating loss	
	5,434
Financing expenses, net	
	12,873
Loss before income tax	
	18,307
Income tax	
	3,477
Income tax	
	140

 	62	
Net loss for the period		
		 	18,447
 	3,539	

QUARTERLY STATEMENTS OF FINANCIAL POSITION (unaudited)

U.S. dollars in thousands

 			
 			
 	 		
March 31,		2019	
 		 	
December 31,		2018	
 			
Assets		 	
 		 	
 		 	
 		 	
 			
Current Assets		 	
 		33,354	
 		 	

left"> </TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">10,432</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </TD>

<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">13,664</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

<TD STYLE="font: bold 10pt Times New Roman, Times, Serif">Equity	</TD><TD STYLE="font-size: 10pt"> </TD>

<TD STYLE="font-size: 10pt; text-align: left"> </TD><TD STYLE="font-size: 10pt; text-align: right"> </TD><TD STYLE="font-size: 10pt; text-align: left"> </TD><TD STYLE="font-size: 10pt"> </TD>

<TD STYLE="font-size: 10pt; text-align: left"> </TD><TD STYLE="font-size: 10pt; text-align: right"> </TD><TD STYLE="font-size: 10pt; text-align: left"> </TD><TD STYLE="font-size: 10pt"> </TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">

<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Total

equity (deficiency)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </TD>

<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">26,348</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </TD>

<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,090</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"></TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total Liabilities and Equity	</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </TD>

<TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">36,780</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </TD>

<TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">12,574</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </TD></TR>

</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CASH FLOWS (unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">U.S. dollars in thousands</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">

<TR STYLE="vertical-align: bottom">

<TD STYLE="font-size: 10pt"> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </TD>

Fiscal Quarter Ended March 31,	
2019	
2018	
Net cash used in operating activities	
	(2,996)
	(2,677)
Net cash used in investing activities	
	(75)
	(104)
Net cash provided by financing activities	
	27,699
	2,000
Net increase (decrease) in cash and cash equivalents	
	24,628
	(781)

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-

color: white"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->

<DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"> </P></DIV>

<!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"></P>

</BODY>

</HTML>

</TEXT>

</DOCUMENT>

<DOCUMENT>

<TYPE>GRAPHIC

<SEQUENCE>3

<FILENAME>image_001.jpg

<DESCRIPTION>GRAPHIC

<TEXT>

begin 644 image_001.jpg

M_]C_X 02D9)1@ ! 0\$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+
M#1D2\$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+P 1" !! 38# 2(A\$! Q\$!_0
M'P 04! 0\$! 0\$ \$" P0%!@<("0H+_0 M1 @\$# P(\$ P4%
M! 0 %] 0(# 01!1(A,4\$&\$U%A!R)Q%#*!D:\$((T*QP152T? D,V)R@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T)?;W^/GZ_\0 'P\$ P\$! 0\$!
M 0\$! 0 \$" P0%!@<("0H+_0 M1\$ @\$" !0#! <%! 0 0)W \$"
M Q\$!2\$Q!A)!40=A<1,B,H\$(%\$*1H;'!"2,S40 58G+1"A8D-.\$E\1<8&1HF
M)R@I*C4V-S@Y.D-\$149'2\$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.\$
MA8:'B(F*DI.4E9:7F)F:HJ.DI:GJ*FJLK.TM;:WN+FZPL/\$Q<;'R,G*TM/4
MU=;7V-G:YN/DY>;GZ.GJ\O/T)?;W^/GZ_]H # ,! (1 Q\$ /P#W^BBF2RQP
M00+*X2-%+,QZ #DF@#)0/>AV&OVNA76H1QZG= && @DMG..<8&<'J:V:^30
M%ESK&J:A_P + 7=':W6H-'9-W018V?AP?Q!KZ<\-ZU#XB\.6&KP8V74*N0/X
M6Z,/P.1^%;U:/)%/^KE-6-6BBBL"0HHIJNICYVLK8ZX.<4 .HHHH **:SH@R[
M*N?4XIV: .;USQYX:\-WWV+5]2%K/M#[6A<C!Z<A2.U6_#WBK10%4\$\^C7@N
MHH'\$;N\$90&(SCY@.U1^+:"[\\$ZW'/\$DB?89FPPS@A"0?J#7G[//'_(LZO\
M]?)B_^@"ME"+I.?5#MI<]CHIN]-^S<N[TSS3JQ\$(S*BEF(50,DDX %0VE[: :A
M!Y]E=0W,.2/,AD#KD=1D54\0:0NO^'[_ \$EYW@6[A:(RIU7/? ZU<Y_ 1\
M!:7=VTFH?);J42,538BX&!@9//J?I5)1Y6[Z@=K1136D1;W5<],G%2 ZBC
M(-% !112\$@#). .] "T4BNKC*L&'J#FEH ***;YB%]@=WIGF@!U%% !11
M0 URP1BJ[F X7.,FN./C34K\$YU?PU>01@RPGS%'^?K79U7N)Q'\B\N>WI5P
ME%?\$K2BWL[%#2/\$VDZV,65XC2=XF^5Q^!K7KGM8\':5JX\TQ?9;P<K<V_RL
M#ZG'6LFUUW5/"Y'I_B10/LY#M@U%1Q]'_S^=7[.,]:>_9_IW)YY1^/[SMZ*
M:K*ZAE8,I&0<@BG5B:A1110 5Y]\7=8GM?"\6AZ>2=2UR9;.%5Z[210/Y\$#
M_@5>@UXK=:9> \$WXH:E<66K3Z=9>'U%M;W4"ACYV3NV\CONY] *UHI<W,]D-
M'9>(/ EO<_"MO"]H@+VMLIMCCK*G.? \ @1S_ -]&N+^ 'B(O::AX;N(>!OM
M,"MUVDX<?@V#_P "-=)_PK;Q)_T4G7/^^?\ [*0*[^QNOA-\5["YENY+JW8B
M9[AEVF6-R5DR/4')_M*Z:4X2A>[W*6JL?3E>-?%WPV^AZ%-XATO6M8@N&NAY
ML7VUS&0Y/W1GY<'ICB08T=9(U=&#(P!4CH17G/QR_P"2:S_]?4/_ *%6%!M5
M\$3'<Y3PA9^(/B1X7LK!])4N],T"PC\$, \T;9GOINK?,?X1D=?U[9_CCX:3_#_2
MU\2>'<U!3;R*)0[X=<G 8%<9&<9!'>O3?A'\$D7PNT38H&Z-V;'<F1LFH_C#
M_P DNUGZ1?\ HQ:V55JKRK:X[ZFKX!\12^*?!6G:M<!1<R(4FVC +J2I(^N,
M_C7._%GXA2^#=#,@L]-VG5KT\$QL1GR4'!?'<YX'X^E2_!3_DF%A_UUF_]&&O.
M/B=_I'QSTN"Z_P"/<-9H >FTOD_J32A3BZS3V5P2U.I\._![^U[&/5/&FIZC
M>:C<J)&A^T\$"/+.">I/TP!6=X_ !.I^"?#TNH>&-?U2+2]Z+=V;W!;8I8 ,
MIZCG /UZU[C4%W:6U]:R6UY!%/;R##QRJ&5A[@UFJ\N:[V["N9?B8Y\#ZN3_
M - Z;_T6:\#^%3:_J^F7GAC0KAM/6>87%]J0Y:&+:%"/[S\$'GT%>_>P!X,
MUH#I_9\^,? \ 7,UYE^SO\$@/\:S* -[72*3[! !C^9K2G*U&3\T-;\$/B'X'Q6.

MCW.I:1KNI/J=O&TP,[@^:5&2,C!/8Y-;_P5\77_(F\W5MJ<S7%SI\BH)W
M.6>-AE=WJ1@C/TKT/40^05>?]<['_ /037C'[_G_'OXA_WH/Y/1S.I2DY=+!N
MCT'QSX2BUNPNM035-3LKR"U;RFM;ID3*@L,H.#_N+^ &H7NHV&NR7MY<7+B
M6\$*T\K.0-K=,F05M:_Y .H_]>LG_*":\@_9T_Y!>O?]=H?_ \$%JF+01E?R!
M; '7?%OQC?>\$/"L<FF@+>7DWD1S\$9\$0P26^O&!_ \ 6K\$#\#" /"OC#PG: :WJ2W
MVJWMRI\^>\N9-PD!PP4!L YQ[5T7Q-\5^'_ YH:0ZYI\>IM<L?)L74\$.5Z
ML2?N@9Z^]<YH-U\2?&\$G0#2].TGPMI&W]SOA+.\$[%4_Q IQO[+33S!; '-ZM+
M>?"?XE:;9:1J5U-H]Y;R6,\I<*K/L(Y[]P>O;FO?)HA-!)\$Q8*ZE25." ?0
M]J^:_B/H']@>.M CGU.YU*_N/+FNKJX;YG;S<# "'J , "OI;<N[;N&[&<9Y
MQ172Y8R\@9[_%S19_!=SI;:7KVL_9KP.) (IKZ1]I7;R#GH0W0^E=;;>%M6^
M*5K'K&NZI>;HT@'V#3;5@'8^@DD)X/7ITK'_:+^ [X>'O/_ .R5[3I<:0Z3
M911J%1(\$50.P"C%5.;5*;EOJ#>B/GQQ9H&J_!S6M.U30M7N9K&X8@QRMU*X)
M1P.&! '0XS7T/87:7^G6MY&"\$N(DE4'L& /\ 60(OVB/^1<T?_K[?_P! ->BZ
M2TB_#VQ: '/FC2HRF/7RABIJOGIQD]P>J/, =8\4:U\2/'K^\$0#U_)I^CVY;[5
M=0'#R*IPS9], \ =^IKJ)/@KX5-H4A;48;0'%XMVQD#>OI^E<-^SN\$;5]==_]
M=]GBQGK@LV?UQ70]%;3IRY(:L)]-\$>+^' _&6M^&/'4G@7Q3=M>(7\$I>2'YL
MD93][JP]>0*]HKY^>,O[OXLZ0]M_P ?'DVY^7KN\T[:^B:5>*M&:ZH'W"BB
MF2RKR#&9'. *YR2.ZN#MX\]6/"KZFJELN7,TK9QRQ/<U &>YF,TG']T=E%.N+
MB*#&#?-*D%NG5Y&"CZDF@&TM6:J.'0,.AYJ'_L+;4[*6TNXA+#(, ,I_F/>N7G
M\>6;M]GT6UEU!UX,OW(5^K'K^ J;3VUK5Y-UQ<B.+^(0+M1?8'JQI*=GH8>V
MA)\L=?R*OAZZN/#FMGPPQ\$ID@<%]/G;^)?[A_P _TKM:Y?QII!NO#_VBURMW
MIQ\$\\##J-04?D/TK9T345U?1K2_3'[Z, ,0.S=Q^>:WJ>_%5%_7_@E0]U\C^1
M?HHHK\$U/.O'GQ3TOP]9WVGZ>\ESK:@Q+% '\$VV%R/O,V,<9S@9S7.? !OQAX>T
MOPY%HUUY/);:M/=LS^;"_]W.%(8#'3 YKV8HA.2JD_2CRT'\'_E6JG'DY;?B
M.ZL*S!\$+,< #)-?/GQH\5>'?%IID6CRR7EY;RL6E2%@JQD<J20,G('3TKZ\$
MIOEI_<7\J5*:A+FL"=CR'X9_%/3/^\$>L=%UV: :VO[?;;Q2/\$Y69>B<@!'Z#G
MTJ0\:/&>C:AX;F\ /V,[W.H"[43(D38BV\$[LDC&<\<5[-Y: ?W%_*CRT[JOY52
MJ14^=+\0NKW/+OA#XRT:3PII/AV2X: '58@\8@DC8;_F9L@XQC'04/QB\9: ,W
MA740#D\$[3ZI(Z10"D3?N\,K\$DXQT'KWKU<(@.0H!^E!1"<E5)^E+VD?:<]@0
MK<\?^#7C/1K7P09^';RX:WU(7+I'\$\38EWMD8. =\<U;^, ?@&^\016NO:+&T
MFI62[7B3[TB [05]64YX[YKU7RT!R%7\J=3]K:I[2(7UN>7^_C1H-UIT<'B
M.=M*U6%=DZ31,9AU(P.,^AQB?B/Q8WQ*9?"?@3RVD\B_VCJ>PI'%\$#DA2
M>I./Z=^/3[01M+OY/,O--L[A_P]- KG\R*L6]M! :0B*V@CAC'1(T"@?@*7/
M! /FBM?P"Z.&\=^+=!\->-%[07G8WQL##!:I&S,0R%5.<8Q^/ :O._@GXOTCPW
M9:CINL3/:27\$Z20N\3%7X"XR!P<@=?6OH HI.2H)]Q56_N\$L8/. -N'0=<8&*
M<:B4'!K<+Z6,'QIXST7PSIUQ! ?W#" [FMG:"W2-F:3((&,# Y):;\ ;^"OB[20"
MDNK6^M2R6BW0B>.5HF*Y7<#"@' '60HMLB*Q4<C/(I?+3^XOY40J1C!P:W! /
M2QQ_C3QSH6A: -=6]U=, UW<V;/;P1Q,S2!@0IX& ,^M>3_!3Q=I/A9=5L]:E>
MT%R8WBE:)BI*@@@X!P>17T044]5!^HH\M/[B_E1&I%0<+;A?2QXE\== 'OFO=
M&2V]N;FRM4V3 D)\X8%0 9/3=-)!<?"\$VG), '0#>, !9);LTA;^Z"/E/
M/?->E,JLI5@"I&"" ."*I6^BZ5:3^?;:990S? \](X%50S H)]I%Q49+8+Z'SE\
M1[;7(]=TCQ=KUL]NM]*&6VQG[+'&P*1L?[Y7+'W]KU;0]>L/%'Q%NM>TR5I=
M(T[2?L[W6Q@K2.^@\9'_%7FN_NK.V08#!=V\5Q">3'*@=3^!HMK2WLX!!:\
M4\$(Z1Q(%4?@*<JRE%*VJ"Y\Z_&GQ;I7BJYTF'199+M+19&DE6)@N6VX R!G[
MM>S^#?&>B^)['&'3[EC=0VZ-;/;0&RM'T!SD8//I73^6G]Q?RI0JKT4#Z"E.I
M&4%&VP-Z6/GWXV>,-(\2V>G:=H\SW;V\SR3.D3!4XV@9(Y/7IZ5Z7\/?&NB:
MYH>F:7;7#+J,%FBRVLD;*R["DY(P1^/>NV\M/[B_E36:&'#,43)P"<#FB52
M+@H6V""^ECPJ[TG4/A%\0Y/\$%M9S77AJ\++ ,85R848Y*D=BIY!/!' '600I?BY
MX(BTXW@UV&0;<B%\$8RD^FW&<_6NV*A@0P! !&""#WK/7P_HR3^>ND6"RYSY@MD
M#9^N*)5(SLYK4+WW/'?'7A_5/B#16<:Q926FEQ2"2TBE&#)MXC 'H.I/OG
MI7N=&,45%2HYOR0-W\$) &3TKG-:URPL_WM=)! OW%)RS_11R:Q_B#X]MO#D
M8TVW#S:C,H;8AQL4],GG!/88KRQ]2UB>8W36.GQ2MSOG1I7_ !WDUM3PE6I'
MF6B\SFJU9+W8+4[VZ\;ZAJ!,6A: ?Y<?3[3=?T7I_.J,>BRZC.+G6;Z2]D])7
MQ&OT'^%<D_B#Q*!QJ4\$?M';(/_9:C&M^*93A-8N6/_3.(?T%7_9M1[R7XG(Z
M4IN]1M_E]QZI:C3K-%41F<KT11LC']375Z1-=7,1EEC2*'(HU7' 'K7A,,GC
M>X(\$5UK4G^Y\$W^%;5CHWQ(NV 6ZU:)?[UQ=>6!^&<_I2^H\F\T=-.\=D>V.B
MR(R,,JP((]17(#UCI=_I['_CSO9(Q[#_./#/A?6K"=+K60\$-W>.OW;=)6
M\L'_ &B>6_2CP.=][XCD'W&U!L?K4<J4)I.^WYFC?OQ?J=A1117.;!1110 4
M444 %%% !1110 4444 %%% %5;R6SMU:) 2[!-Q/3-0ZP\CZ//YD7ED%<
M? ,#GD5+K%0+<6:^2N]TD5]OKBHM2>:\TYXX[6;<Q& 1CODT 3?V@8'MXY8'5
M)<*KY'7W':IY;K;<"WC3S)2N\C. ! [FL^_\$LPL3';3'RW#N-00"B>&1-5^V&
MW>:"6,*R@99#]* +D5^)K626.,EXB0\9.""M16^J_:#!BUF"S9P^,@5(%"6
ML[1VICW@*]_,QQU(IND*\6G10RQNCB,\$,/>@!KZLBQR3"%V@C?8SYQS[#04
MEW?_ &22\$&G65@JLI[_ \$K,N(;VYM;B*2T=IM^X/D;=N>BBIM1D<II[M\$RG
MSA\AZT 71?E;Q+>>!HC)_JV]!#>W'0T2:A@3M%"94@.)"#CGOCUQ45Q')>W]

MJRQND4#%V=QC)]!5>VMVLY[B*>T>9'<NCHN<Y['TH MRZFB?9F2,O'<\$!6!Z
M\$^M2&^*ZBMFT)!92P?(Q@540K:7R;1XK<#R)0YBC[#VH?SGUFWN?LTHB\$94D
MCD9]10!(M]<OJDUNL *QIG;N&3G02ZG-'&D(N+7S49P!\WW6IA26VUF: ?R))
M(I8P 4&<\$>M&K+--# L<#LXD5V"C. />@"W+=A;D6T:&28KN(S@ >YJ)=3B-
ME-<E'7R25=#U!J"1)X-6^VI"\D,L85@H^9?PJS,\K6Q9;4D%ANC.,LO>@"2&
MY:60*8P%*;U=6W U8K,T^U:VNY/)\$BVC+G9)V;/:M.@#PKQO926_Q6EENE/E
MW,2R6['H<)MX^A!K.N.IKW+7/#VG>(;5(;^'<8VWQ2J</&WJI[?R-<_>?#NP
MEE!@D98FP)(VZC_:1NQ]CD&O2IXR'+%2Z:&7LVKV/'):L6>D7FHN%L9())#T
MC%PJ/^3\$5Z/%\,KB"] -Y:75B3\T=Q\$P?'L5/!^AK3;X6>&VDW%;O'7;Y_'\
MLUK+&4ULR?9L^M_ _C1G"QV]Q#[M=!1^C5WGA3P5JFFW*7FL:U<SLG*VL<[
MF//^T2?F^G2NPT_3[?3+*.TM49(8QA0SEC^9)-6JXJN+G-6TMZ&D::15U&\C
MT[3KF\E("0QLYS["L#X?VCP>%TN)1^\O)7N&_\$?H*Z6XMX;J!X)XUEB<;71
MQD,/>EBB2&)(HD5(T 5548 ["L%.T' 'N#C>:D/HHHJ"PHHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ K*UG_6V'_7<444 :M%% !1110
B4444 %%% !1110 4444 %%% !1110 4444 %%% '_V0\$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>